

Peer Reviewed Cannabis and Cancer References

1. Argaw, A. et al. Concerted Action of CB1 Cannabinoid Receptor and Deleted in Colorectal Cancer in Axon Guidance. *J Neurosci* 31, 1489-1499 (2011).
2. Malfitano, A. M. et al. Update on the endocannabinoid system as an anticancer target. *Expert Opin Ther Targets* (2011).
3. Lorente, M. et al. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. *Cell Death Differ* (2011).
4. Karasu, T., Marczylo, T. H., Maccarrone, M. & Konje, J. C. The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. *Hum Reprod Update* (2011).
5. Torres, S. et al. A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. *Mol Cancer Ther* 10, 90-103 (2011).
6. Hsu, E. S. A review of granisetron, 5-hydroxytryptamine₃ receptor antagonists, and other antiemetics. *Am J Ther* 17, 476-486 (2010).
7. Van Ryckeghem, F. & Van Belle, S. Management of chemotherapy-induced nausea and vomiting. *Acta Clin Belg* 65, 305-310 (2010).
8. Jordan, K. et al. Antiemetics in children receiving chemotherapy. *MASCC/ESMO guideline update 2009*. *Support Care Cancer* (2010).
9. Liu, W. M., Fowler, D. W. & Dalgleish, A. G. Cannabis-Derived Substances in Cancer Therapy - an Emerging Anti-Inflammatory Role for the Cannabinoids. *Curr Clin Pharmacol* (2010).
10. Larrinaga, G. et al. Cannabinoid CB1 Receptor Is Down-regulated in Clear Cell Renal Cell Carcinoma. *J Histochem Cytochem* (2010).
11. Lam, P. M., Marczylo, T. H. & Konje, J. C. Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem* (2010).
12. Tazi, E. & Errihani, H. Treatment of cachexia in oncology. *Indian J Palliat Care* 16, 129-137 (2010).
13. Thapa, D. et al. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis. *Eur J Pharmacol* (2010).
14. Amoako, A. A. et al. Quantitative analysis of anandamide and related acylethanolamides in human seminal plasma by ultra performance liquid chromatography tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* (2010).

15. Peat, S. Using cannabinoids in pain and palliative care. *Int J Palliat Nurs* 16, 481- 485 (2010).
16. Hu, G., Ren, G. & Shi, Y. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. *Oncogene* (2010).
17. Preet, A. et al. Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis. *Cancer Prev Res (Phila)* (2010).
18. Saghafi, N., Lam, D. K. & Schmidt, B. L. Cannabinoids Attenuate Cancer Pain and Proliferation in a Mouse Model. *Neurosci Lett* (2010).
19. Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S. & Huestis, M. A. Plasma Cannabinoid Pharmacokinetics following Controlled Oral Δ^9 -Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration. *Clin Chem* (2010).
20. Lin, H. C. et al. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. *J Hepatol* (2010).
21. Duran, M. et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. *Br J Clin Pharmacol* 70, 656-663 (2010).
22. Lee, T. Y., Lee, K. C. & Chang, H. H. Modulation of the cannabinoid receptors by andrographolide attenuates hepatic apoptosis following bile duct ligation in rats with fibrosis. *Apoptosis* (2010).
23. Yang, Q., Liu, H. Y., Zhang, Y. W., Wu, W. J. & Tang, W. X. Anandamide induces cell death through lipid rafts in hepatic stellate cells. *J Gastroenterol Hepatol* (2010).
24. Labar, G., Wouters, J. & Lambert, D. M. A Review on the Monoacylglycerol Lipase: At the Interface between Fat and Endocannabinoid Signalling. *Curr Med Chem* (2010).
25. Frampton, G., Coufal, M., Li, H., Ramirez, J. & Demorrow, S. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. *Exp Cell Res* (2010).
26. Xian, X. S. et al. Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells. *J Cell Biochem* (2010).
27. Jesus, M. L. et al. Opposite changes in cannabinoid CB(1) and CB(2) receptor expression in human gliomas. *Neurochem Int* (2010).
28. Laezza, C. et al. Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell. *Endocr Relat Cancer* (2010).

29. Wu, W. J. et al. [Membrane cholesterol mediates the endocannabinoids-anandamide effect on HepG2 cells.]. *Zhonghua Gan Zang Bing Za Zhi* 18, 204-208 (2010).
30. Fonseca, B. M. et al. N-Acylethanolamine Levels and Expression of Their Metabolizing Enzymes during Pregnancy. *Endocrinology* (2010).
31. Fernandez-Solari, J., Prestifilippo, J. P., Ossola, C. A., Rettori, V. & Elverdin, J. C. Participation of the endocannabinoid system in lipopolysaccharide-induced inhibition of salivary secretion. *Arch Oral Biol* (2010).
32. Whyte, D. A. et al. Cannabinoids Inhibit Cellular Respiration of Human Oral Cancer Cells. *Pharmacology* 85, 328-335 (2010).
33. Soneji, N. D., Paule, C. C., Mlynarczyk, M. & Nagy, I. Effects of cannabinoids on capsaicin receptor activity following exposure of primary sensory neurons to inflammatory mediators. *Life Sci* (2010).
34. Reiss, C. S. Cannabinoids and Viral Infections. *Pharmaceuticals (Basel)* 3, 1873- 1886 (2010).
35. Santha, P., Jenes, A., Somogyi, C. & Nagy, I. The endogenous cannabinoid anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated currents in rat cultured primary sensory neurons. *Acta Physiol Hung* 97, 149-158 (2010).
36. Ford, L. A. et al. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. *Br J Pharmacol* 160, 762-771 (2010).
37. Brown, I. et al. Cannabinoid receptor dependent and independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor positive and negative prostate cancer cell lines. *Carcinogenesis* (2010).
38. Caffarel, M. M. et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. *Mol Cancer* 9, 196 (2010).
39. Park, J. Y. et al. Alcohol intake and risk of colorectal cancer: Results from the UK Dietary Cohort Consortium. *Br J Cancer* (2010).
40. Linsalata, M. et al. Effects of anandamide on polyamine levels and cell growth in human colon cancer cells. *Anticancer Res* 30, 2583-2589 (2010).
41. Marcu, J. P. et al. Cannabidiol Enhances the Inhibitory Effects of Δ^9 -Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival. *Mol Cancer Ther* (2010).
42. Petrosino, S. & Di Marzo, V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. *Curr Opin Investig Drugs* 11, 51-62 (2010).

43. Patel, K. D., Davison, J. S., Pittman, Q. J. & Sharkey, K. A. Cannabinoid CB(2) Receptors in Health and Disease. *Curr Med Chem* (2010).
44. Martini, L., Thompson, D., Kharazia, V. & Whistler, J. L. Differential Regulation of Behavioral Tolerance to WIN55,212-2 by GASP1. *Neuropsychopharmacology* (2010).
45. Gao, M., Wang, M., Miller, K. D., Hutchins, G. D. & Zheng, Q. H. Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging. *Bioorg Med Chem* (2010).
46. Zoppi, S. et al. Regulatory Role of Cannabinoid Receptor 1 in Stress-Induced Excitotoxicity and Neuroinflammation. *Neuropsychopharmacology* (2010).
47. Cui, J. H. et al. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. *Neurosci Lett* (2010).
48. Kalifa, S., Polston, E. K., Allard, J. S. & Manaye, K. F. Distribution Patterns of Cannabinoid CB1 receptors in the hippocampus of APP(swe)/PS1(DeltaE9) double transgenic mice. *Brain Res* (2010).
49. De Petrocellis, L. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol* (2010).
50. Miro, A. M. et al. 17beta-Estradiol regulates oxidative stress in prostate cancer cell lines according to ERalpha/ERbeta ratio. *J Steroid Biochem Mol Biol* (2010).
51. Nithipatikom, K., Isbell, M. A., Endsley, M. P., Woodliff, J. E. & Campbell, W. B. Anti-proliferative Effect of a Putative Endocannabinoid; 2-Arachidonylglycerol Ether in Prostate Carcinoma Cells. *Prostaglandins Other Lipid Mediat* (2010).
52. Nunez, M., Perdomo, S., Moreta, J., Santos-Briz, A. & Gonzalez-Sarmiento, R. The G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients. *Clin Transl Oncol* 12, 825-828 (2010).
53. Ward, H., Luben, R. N., Wareham, N. J. & Khaw, K. T. CHD risk in relation to alcohol intake from categorical and open-ended dietary instruments. *Public Health Nutr* 1-8 (2010).
54. Yang, Y. Y., Liu, H., Nam, S. W., Kunos, G. & Lee, S. S. Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. *J Hepatol* 53, 298-306 (2010).
55. Miranville, A., Herling, A. W., Biemer-Daub, G. & Voss, M. D. Reversal of Inflammation-Induced Impairment of Glucose Uptake in Adipocytes by Direct Effect of CB1 Antagonism on Adipose Tissue Macrophages. *Obesity (Silver Spring)* (2010).

56. Kawamata, T., Niiyama, Y., Yamamoto, J. & Furuse, S. Reduction of bone cancer pain by CB1 activation and TRPV1 inhibition. *J Anesth* (2010).
57. Fowler, C. J. et al. Targeting the Endocannabinoid System for the Treatment of Cancer - A Practical View. *Curr Top Med Chem* (2010).
58. Taylor, A. H., Abbas, M. S., Habiba, M. A. & Konje, J. C. Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. *Histochem Cell Biol* (2010).
59. Gallotta, D. et al. Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways. *Biochem Pharmacol* (2010).
60. Mukhopadhyay, B. et al. Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor- γ . *J Biol Chem* (2010).
61. De Laurentiis, A., Fernandez Solari, J., Mohn, C., Zorrilla Zubilete, M. & Rettori, V. Endocannabinoid System Participates in Neuroendocrine Control of Homeostasis. *Neuroimmunomodulation* 17, 153-156 (2010).
62. Thors, L. et al. Fatty Acid Amide Hydrolase in Prostate Cancer: Association with Disease Severity and Outcome, CB(1) Receptor Expression and Regulation by IL-4. *PLoS One* 5, (2010).
63. Phillips, R. S. et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. *Cochrane Database Syst Rev* 9, CD007786 (2010).
64. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. The cannabinoid R(+)-methanandamide induces IL-6 secretion by prostate cancer PC3 cells. *J Immunotoxicol* (2009).
65. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. Non- psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol Sci* (2009).
66. Wainwright, C. & McGrath, J. Editorial. *Br J Pharmacol* 158, 393-394 (2009).
67. Guindon, J. & Hohmann, A. G. The Endocannabinoid System and Pain. *CNS*
68. *Neurol Disord Drug Targets* (2009).
69. Horn, C. C., Still, L., Fitzgerald, C. & Friedman, M. I. Food restriction, refeeding, and gastric fill fail to affect emesis in musk shrews. *Am J Physiol Gastrointest Liver Physiol* (2009).

70. Freimuth, N., Ramer, R. & Hinz, B. Antitumorigenic effects of cannabinoids beyond apoptosis. *J Pharmacol Exp Ther* (2009).
71. Tournier, N. et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). *Int J Neuropsychopharmacol* 1-11 (2009).
72. Johnson, J. R. et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable Cancer-Related Pain. *J Pain Symptom Manage* (2009).
73. Qamri, Z. et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. *Mol Cancer Ther* (2009).
74. Rask-Andersen, M., Olszewski, P. K., Levine, A. S. & Schioth, H. B. Molecular mechanisms underlying anorexia nervosa: Focus on human gene association studies and systems controlling food intake. *Brain Res Rev* (2009).
75. De Filippis, D. et al. LEVELS OF ENDOCANNABINOIDS AND PALMITOYLETHANOLAMIDE AND THEIR PHARMACOLOGICAL MANIPULATION IN CHRONIC GRANULOMATOUS INFLAMMATION IN RATS. *Pharmacol Res* (2009).
76. Leelawat, S., Leelawat, K., Narong, S. & Matangkasombut, O. The Dual Effects of Delta(9)-Tetrahydrocannabinol on Cholangiocarcinoma Cells: Anti-Invasion Activity at Low Concentration and Apoptosis Induction at High Concentration. *Cancer Invest* (2009).
77. Ramer, R., Merkord, J., Rohde, H. & Hinz, B. Cannabidiol Inhibits Cancer Cell Invasion Via Upregulation Of Tissue Inhibitor Of Matrix Metalloproteinases-1. *Biochem Pharmacol* (2009).
78. Brighton, P. J. et al. Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells. *Mol Endocrinol* (2009).
79. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids, their congeners and COX-2 metabolites. *J Chromatogr B Analyt Technol Biomed Life Sci* (2009).
80. Takeda, S., Yamamoto, I. & Watanabe, K. Modulation of Delta(9)- tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase. *Toxicology* 259, 25-32 (2009).

81. Cotter, J. Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic Literature Review. *Oncol Nurs Forum* 36, 345-352 (2009).
82. Wegener, N. & Koch, M. Neurobiology and Systems Physiology of the Endocannabinoid System. *Pharmacopsychiatry* 42, S79-S86 (2009)
83. Brizzi, A. et al. New Resorcinol-Anandamide "Hybrids" as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. *J Med Chem* (2009).
84. Izzo, A. A. & Camilleri, M. Cannabinoids in intestinal inflammation and cancer. *Pharmacol Res* (2009).
85. Yin, H. et al. Lipid G-protein-coupled Receptor Ligand Identification Using beta - arrestin Pathhunter Assay. *J Biol Chem* (2009).
86. Villanueva, A. et al. Central Cannabinoid-1 Receptor Antagonist Administration Prevents Endotoxic Hypotension Affecting Norepinephrine Release in the Preoptic Anterior Hypothalamic Area. *Shock* (2009).
87. Farquhar-Smith, W. P. Do cannabinoids have a role in cancer pain management? *Curr Opin Support Palliat Care* 3, 7-13 (2009).
88. Navari, R. M. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. *Expert Opin Pharmacother* 10, 629-644 (2009).
89. Oesch, S. et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. *Mol Cancer Ther* (2009).
90. Furuse, S. et al. Reduction of Bone Cancer Pain by Activation of Spinal Cannabinoid Receptor 1 and Its Expression in the Superficial Dorsal Horn of the Spinal Cord in a Murine Model of Bone Cancer Pain. *Anesthesiology* (2009).
91. Schley, M. et al. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. *Brain Res Bull* 79, 333-337 (2009).
92. Udler, M. S. et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. *Int J Cancer* (2009).
93. Luca, T. et al. The CB(1)/CB(2) receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro. *Eur J Pharmacol* (2009).
94. Galal, A. M. et al. Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications. *Recent Pat CNS Drug Discov* 4, 112-136 (2009).
95. Liang, C. et al. A Population-Based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma. *Cancer Prev Res (Phila Pa)* (2009).

96. Surtees, P. G., Wainwright, N. W., Luben, R. N., Khaw, K. T. & Bingham, S. A. No evidence that social stress is associated with breast cancer incidence. *Breast Cancer Res Treat* (2009).
97. Biro, T., Toth, B. I., Hasko, G., Paus, R. & Pacher, P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. *Trends Pharmacol Sci* (2009).
98. Han, K. H. et al. CB1 and CB2 Cannabinoid Receptors Differentially Regulate the Production of Reactive Oxygen Species by Macrophages. *Cardiovasc Res* (2009).
99. Oesch, S. & Gertsch, J. Cannabinoid receptor ligands as potential anticancer agents - high hopes for new therapies? *J Pharm Pharmacol* 61, 839-853 (2009).
100. Gustafsson, K., Sander, B., Bielawski, J., Hannun, Y. A. & Flygare, J. Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. *Mol Cancer Res* 7, 1086-1098 (2009).
101. Ramesh, Shukla, N. K. & Bhatnagar, S. Phantom breast syndrome. *Indian J Palliat Care* 15, 103-107 (2009).
102. Surtees, P. G. et al. No association between APOE and major depressive disorder in a community sample of 17,507 adults. *J Psychiatr Res* (2009).
103. Dunning, A. M. et al. Association of ESR1 gene tagging SNPs with breast cancer risk. *Hum Mol Genet* (2009).
104. Van Dross, R. T. Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes. *Mol Carcinog* (2009).
105. Lorente, M. et al. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. *Glia* (2009).
106. Pisanti, S. et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. *Best Pract Res Clin Endocrinol Metab* 23, 117-131 (2009).
107. Froger, N. et al. Cannabinoids prevent the opposite regulation of astroglial connexin43 hemichannels and gap junction channels induced by pro-inflammatory treatments. *J Neurochem* 111, 1383-1397 (2009).
108. Madeddu, C. & Mantovani, G. An update on promising agents for the treatment of cancer cachexia. *Curr Opin Support Palliat Care* (2009).
109. Mantovani, G. & Madeddu, C. Cancer cachexia: medical management. *Support Care Cancer* (2009).

110. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB(2). *Br J Cancer* (2009).
111. Zhao, P., Leonoudakis, D., Abood, M. E. & Beattie, E. Cannabinoid Receptor Activation Reduces TNFalpha-Induced Surface Localization of AMPAR-Type Glutamate Receptors and Excitotoxicity. *Neuropharmacology* (2009).
112. Pisanti, S. & Bifulco, M. Endocannabinoid system modulation in cancer biology and therapy. *Pharmacol Res* 60, 107-116 (2009).
113. Moayyeri, A. et al. Estimation of absolute fracture risk among middle-aged and older men and women: the EPIC-Norfolk population cohort study. *Eur J Epidemiol* (2009).
114. Santoro, A. et al. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. *Int J Cancer* (2009).
115. Wang, Q. et al. Pretreatment With Electroacupuncture Induces Rapid Tolerance to Focal Cerebral Ischemia Through Regulation of Endocannabinoid System. *Stroke* (2009).
116. Gallant, M., Odei-Addo, F., Frost, C. L. & Levendal, R. A. Biological effects of THC and a lipophilic cannabis extract on normal and insulin resistant 3T3-L1 adipocytes. *Phytomedicine* (2009).
117. Salazar, M. et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *J Clin Invest* (2009).
118. El-Talatini, M. R. et al. Localisation and function of the endocannabinoid system in the human ovary. *PLoS ONE* 4, e4579 (2009).
119. Keeley, P. W. Nausea and vomiting in people with cancer and other chronic diseases. *Clin Evid (Online)* 2009, (2009).
120. Alpini, G. & Demorrow, S. Chapter 18 Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer. *Vitam Horm* 81C, 469-485 (2009).
121. Bifulco, M., Santoro, A., Laezza, C. & Malfitano, A. M. Chapter 7 Cannabinoid Receptor CB1 Antagonists State of the Art and Challenges. *Vitam Horm* 81, 159- 189 (2009).
122. Wang, J. et al. Expression and secretion of N-acyl ethanolamine-hydrolyzing acid amidase in human prostate cancer cells. *J Biochem* (2008).
123. Zuardi, A. W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. *Rev Bras Psiquiatr* 30, 271-280 (2008).

124. Khasabova, I. A. et al. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. *J Neurosci* 28, 11141-11152 (2008).
125. Eichele, K., Ramer, R. & Hinz, B. R(+)-Methanandamide-Induced Apoptosis of Human Cervical Carcinoma Cells Involves A Cyclooxygenase-2-Dependent Pathway. *Pharm Res* (2008).
126. Demorrow, S. et al. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. *Am J Physiol Gastrointest Liver Physiol* 294, G506-19 (2008).
127. Van der Kooy, F., Pomahacova, B. & Verpoorte, R. Cannabis Smoke Condensate II: Influence of Tobacco on Tetrahydrocannabinol Levels. *Inhal Toxicol* 1 (2008).
128. Burstein, S. & Salmonsén, R. Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation. *Bioorg Med Chem* (2008).
129. Czifra, G. et al. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. *J Cancer Res Clin Oncol* (2008).
130. Lissoni, P. et al. The endocannabinoid anandamide neither impairs in vitro T-cell function nor induces regulatory T-cell generation. *Anticancer Res* 28, 3743-3748 (2008).
131. Giuliano, M. et al. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: Involvement of the transcription factor PPARgamma. *Biochimie* (2008).
132. Purohit, V., Gao, B. & Song, B. J. Molecular Mechanisms of Alcoholic Fatty Liver. *Alcohol Clin Exp Res* (2008).
133. Caffarel, M. M. et al. JunD is involved in the antiproliferative effect of Delta(9)-tetrahydrocannabinol on human breast cancer cells. *Oncogene* (2008).
134. Casida, J. E., Nomura, D. K., Vose, S. C. & Fujioka, K. Organophosphate-sensitive lipases modulate brain lysophospholipids, ether lipids and endocannabinoids. *Chem Biol Interact* (2008).
135. Buznikov, G. A. et al. Amyloid Precursor Protein 96-110 and Beta-amyloid 1-42 Elicit Developmental Anomalies in Sea Urchin Embryos and Larvae That Are Alleviated By Neurotransmitter Analogs for Acetylcholine, Serotonin and Cannabinoids. *Neurotoxicol Teratol* (2008).
136. Zheng, D. et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. *Cancer Res* 68, 3992-3998 (2008).
137. Deutsch, S. I. et al. Current Status of Cannabis Treatment of Multiple Sclerosis with an Illustrative Case Presentation of a Patient with MS, Complex Vocal Tics, Paroxysmal

- Dystonia, and Marijuana Dependence Treated with Dronabinol. *CNS Spectr* 13, 393-403 (2008).
138. Surtees, P. G. et al. Psychological distress, major depressive disorder, and risk of stroke. *Neurology* 70, 788-794 (2008).
 139. De Petrocellis, L. et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 (TRPA1) and melastatin type-8 (TRPM-8). *J Pharmacol Exp Ther* (2008).
 140. Blazquez, C. et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. *Cancer Res* 68, 1945-1952 (2008).
 141. Endsley, M. P. et al. Expression and Function of Fatty Acid Amide Hydrolase in Prostate Cancer. *Int J Cancer* (2008).
 142. Iribarne, M. et al. Cannabinoid Receptors in Conjunctival Epithelium: Identification and Functional Properties. *Invest Ophthalmol Vis Sci* (2008).
 143. Gustafsson, K. et al. Expression of Cannabinoid Receptors Type 1 and Type 2 in Non-hodkin Lymphoma: Growth Inhibition By Receptor Activation. *Int J Cancer* (2008).
 144. Bifulco, M., Malfitano, A. M., Pisanti, S. & Laezza, C. Endocannabinoids in endocrine and related tumours. *Endocr Relat Cancer* 15, 391-408 (2008).
 145. Widmer, M., Hanemann, O. & Zajicek, J. High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. *J Neurosci Res* (2008).
 146. Habayeb, O. M., Taylor, A. H., Bell, S. C., Taylor, D. J. & Konje, J. C. Expression of the Endocannabinoid System in Human First Trimester Placenta and its Role in Trophoblast Proliferation. *Endocrinology* (2008).
 147. Machado Rocha, F. C., Stefano, S. C., DE Cassia Haiek, R., Rosa Oliveira, L. M. & DA Silveira, D. X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. *Eur J Cancer Care (Engl)* (2008).
 148. Rahn, E. J. et al. Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats. *J Pharmacol Exp Ther* (2008).
 149. van Diepen, H., Schlicker, E. & Michel, M. C. Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). *Naunyn Schmiedebergs Arch Pharmacol* (2008).

150. Gustafsson, S. B., Lindgren, T., Jonsson, M. & Jacobsson, S. O. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. *Cancer Chemother Pharmacol* (2008).
151. von Bueren, A. O., Schlumpf, M. & Lichtensteiger, W. Delta(9)- tetrahydrocannabinol inhibits 17beta-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. *Anticancer Res* 28, 85-89 (2008).
152. Ramer, R. & Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. *J Natl Cancer Inst* 100, 59-69 (2008).
153. Sarfaraz, S., Adhami, V. M., Syed, D. N., Afaq, F. & Mukhtar, H. Cannabinoids for cancer treatment: progress and promise. *Cancer Res* 68, 339-342 (2008).
154. Warr, D. G. Chemotherapy- and cancer-related nausea and vomiting. *Curr Oncol* 15, S4-9 (2008).
155. Jones, J. D., Carney, S. T., Vrana, K. E., Norford, D. C. & Howlett, A. C. Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells. *Neuropharmacology* 54, 23-30 (2008).
156. Bari, M. et al. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. *Neuropharmacology* 54, 45-50 (2008).
157. Blazquez, C. et al. Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? *Neuropharmacology* 54, 235-243 (2008).
158. Notarnicola, M. et al. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. *Scand J Gastroenterol* 43, 66-72 (2008).
159. Shi, Y. et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. *Cancer Gene Ther* 15, 101-107 (2008).
160. Massi, P. et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. *J Neurochem* 104, 1091-1100 (2008).
161. Rudolph, M. I. et al. The Influence of Mast Cell Mediators on Migration of SW756 Cervical Carcinoma Cells. *J Pharmacol Sci* 106, 208-218 (2008).
162. Ware1, M. A., Daeninck, P. & Maida, V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. *Ther Clin Risk Manag* 4, 99-107 (2008).

163. Russo, E. B. Cannabinoids in the management of difficult to treat pain. *Ther Clin Risk Manag* 4, 245-259 (2008).
164. Diaz, P. et al. 6-Methoxy-N-alkyl Isatin Acylhydrazone Derivatives as a Novel Series of Potent Selective Cannabinoid Receptor 2 Inverse Agonists: Design, Synthesis, and Binding Mode Prediction. *J Med Chem* (2008).
165. Sugamura, K. et al. Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages. *Circulation* (2008).
166. Chung, S. C. et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. *Eur J Cancer* (2008).
167. Cianchi, F. et al. Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor α -Mediated Ceramide De novo Synthesis in Colon Cancer Cells. *Clin Cancer Res* 14, 7691-7700 (2008).
168. Anand, P., Whiteside, G., Fowler, C. J. & Hohmann, A. G. Targeting CB(2) receptors and the endocannabinoid system for the treatment of pain. *Brain Res Rev* (2008).
169. Yazulla, S. Endocannabinoids in the retina: From marijuana to neuroprotection. *Prog Retin Eye Res* (2008).
170. Wang, D. et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. *Cancer Res* 68, 6468-6476 (2008).
171. Santoro, A. et al. Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: Implications for the development of colorectal cancer". *Int J Cancer* (2008).
172. Potenzieri, C., Harding-Rose, C. & Simone, D. A. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. *Brain Res* (2008).
173. Ernst, G. & Kongsgaard, U. E. [Use of cannabinoids in palliative medicine.]. *Tidsskr Nor Laegeforen* 128, 822-825 (2008).
174. DUBOIS. Turned-off Cannabinoid Receptor Turns on Colorectal Tumor Growth. *Newswise* (2008).
175. Bilsland, L. G. & Greensmith, L. The endocannabinoid system in amyotrophic lateral sclerosis. *Curr Pharm Des* 14, 2306-2316 (2008).
176. Massi, P., Valenti, M., Bolognini, D. & Parolaro, D. Expression and function of the endocannabinoid system in glial cells. *Curr Pharm Des* 14, 2289-2298 (2008).

177. Galanti, G. et al. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. *Acta Oncol* 47, 1062-1070 (2008).
178. Izzo, A. A. et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. *J Mol Med* (2007).
179. Izzo, A. A. The cannabinoid CB(2) receptor: a good friend in the gut. *Neurogastroenterol Motil* 19, 704-708 (2007).
180. Peters, M. & Kogan, N. M. HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. *Expert Opin Investig Drugs* 16, 1405-1413 (2007).
181. Michalski, C. W. et al. Cannabinoids in pancreatic cancer: Correlation with survival and pain. *Int J Cancer* (2007).
182. Holland, M. L., Lau, D. T., Allen, J. D. & Arnold, J. C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. *Br J Pharmacol* (2007).
183. Mukhopadhyay, S. & Tulis, D. A. Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. *Cardiovasc Hematol Agents Med Chem* 5, 311-318 (2007).
184. Gary-Bobo, M. et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. *Hepatology* (2007).
185. Seamon, M. J., Fass, J. A., Maniscalco-Feichtl, M. & Abu-Shraie, N. A. Medical marijuana and the developing role of the pharmacist. *Am J Health Syst Pharm* 64, 1037-1044 (2007).
186. Varvel, S. A., Martin, B. R. & Lichtman, A. H. Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine. *Psychopharmacology (Berl)* (2007).
187. Slatkin, N. E. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. *J Support Oncol* 5, 1-9 (2007).
188. Tham, C. S., Whitaker, J., Luo, L. & Webb, M. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. *FEBS Lett* 581, 2899-2904 (2007).
189. Taylor, A. H., Ang, C., Bell, S. C. & Konje, J. C. The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. *Hum Reprod Update* (2007).
190. Greenhough, A., Patsos, H. A., Williams, A. C. & Paraskeva, C. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. *Int J Cancer* (2007).

191. Gkoumassi, E. et al. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. *Br J Pharmacol* (2007).
192. Preet, A., Ganju, R. K. & Groopman, J. E. Delta(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. *Oncogene* (2007).
193. Vila, A., Rosengarth, A., Piomelli, D., Cravatt, B. & Marnett, L. J. Hydrolysis of Prostaglandin Glycerol Esters by the Endocannabinoid-Hydrolyzing Enzymes, Monoacylglycerol Lipase and Fatty Acid Amide Hydrolase. *Biochemistry* (2007).
194. Udler, M. et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. *J Clin Oncol* 25, 3015-3023 (2007).
195. Schramm-Sapyta, N. L. et al. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. *Psychopharmacology (Berl)* S (2007).
196. Jordan, K., Schmoll, H. J. & Aapro, M. S. Comparative activity of antiemetic drugs. *Crit Rev Oncol Hematol* S (2007).
197. Aguado, T. et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. *J Biol Chem* S (2007).
198. Demorrow, S. et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: Recruitment of fas and fas ligand to lipid rafts. *J Biol Chem* S (2007).
199. Bifulco, M., Grimaldi, C., Gazerro, P., Pisanti, S. & Santoro, A. Rimonabant: Just an Anti-obesity Drug? Current Evidence on Its Pleiotropic Effects. *Mol Pharmacol* (2007).
200. Darmani, N. A., Janoyan, J. J., Crim, J. & Ramirez, J. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. *Eur J Pharmacol* S (2007).
201. Fogarty, A. et al. Marijuana as therapy for people living with HIV/AIDS: Social and health aspects. *AIDS Care* S 19, 295-301 (2007).
202. Athanasiou, A. et al. Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. *Biochem Biophys Res Commun* 364, 131-137 (2007).
203. Takeda, S. et al. Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. *Toxicology* (2007).
204. Flygare, J. & Sander, B. The endocannabinoid system in cancer-Potential therapeutic target? *Semin Cancer Biol* (2007).
205. Engels, F. K. et al. Medicinal cannabis in oncology. *Eur J Cancer* 43, 2638-2644 (2007).

206. Russo, E. B., Guy, G. W. & Robson, P. J. Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex((R)), a Cannabis-Based Medicine. *Chem Biodivers* 4, 1729-1743 (2007).
207. Zhang, X., Wang, J. F., Kunos, G. & Groopman, J. E. Cannabinoid Modulation of Kaposi's Sarcoma Associated Herpesvirus Infection and Transformation. *Cancer Res* 67, 7230-7237 (2007).
208. Kempf, K. et al. Immune-mediated Activation of the Endocannabinoid System in Visceral Adipose Tissue in Obesity. *Horm Metab Res* 39, 596-600 (2007).
209. Batkai, S. et al. Decreased age-related cardiac dysfunction, myocardial nitrate stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. *Am J Physiol Heart Circ Physiol* 293, H909-18 (2007).
210. Velasco, G. et al. Cannabinoids and gliomas. *Mol Neurobiol* 36, 60-67 (2007).
211. De Filippis, D. et al. Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. *J Mol Med* (2007).
212. Bifulco, M., Laezza, C., Gazerro, P. & Pentimalli, F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review). *Oncol Rep* 17, 813-816 (2007).
213. D'Souza, D. C. Cannabinoids and psychosis. *Int Rev Neurobiol* 78, 289-326 (2007).
214. Whiteside, G. T., Lee, G. P. & Valenzano, K. J. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. *Curr Med Chem* 14, 917-936 (2007).
215. Sunil K. Aggarwal, M. S. I. I. I., PhC, BS, BA, Muraco Kyashna-Tocha, PhD; Gregory T. Carter, MD, MS. Dosing Medical Marijuana: Rational Guidelines on Trial in Washington State. (2007).
216. Kingsley, P. J. & Marnett, L. J. LC-MS-MS Analysis of Neutral Eicosanoids. *Methods Enzymol* 433, 91-112 (2007).
217. Kogan, N. M. & Mechoulam, R. Cannabinoids in health and disease. *Dialogues Clin Neurosci* 9, 413-430 (2007).
218. Goanvic, D. L. & Tius, M. A. Oxaza adamantyl cannabinoids. A new class of cannabinoid receptor probes. *J Org Chem* 71, 7800-7804 (2006).
219. Pacher, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev* 58, 389-462 (2006).
220. Karanian, D. A. & Bahr, B. A. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. *Curr Mol Med* 6, 677-684 (2006).

221. Ziring, D. et al. Formation of B and T cell subsets require the cannabinoid receptor CB2. *Immunogenetics* 58, 714-725 (2006).
222. Ligresti, A. et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther* 318, 1375- 1387 (2006).
223. Sarfaraz, S., Afaq, F., Adhami, V. M., Malik, A. & Mukhtar, H. Cannabinoid receptor agonist induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. *J Biol Chem* (2006).
224. Blazquez, C. et al. Cannabinoid receptors as novel targets for the treatment of melanoma. *FASEB J* (2006).
225. Stokes, A. et al. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. *Cell Signal* 18, 1584-1594 (2006).
226. De Lago, E. et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. *J Neurochem* 99, 677-688 (2006).
227. Xu, X. et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. *Cancer Genet Cytogenet* 171, 31-38 (2006).
228. Fernandez-Solari, J., Prestifilippo, J. P., Bornstein, S. R., McCann, S. M. & Rettori, V. Participation of the Endocannabinoid System in the Effect of TNF- α on Hypothalamic Release of Gonadotropin-Releasing Hormone. *Ann N Y Acad Sci* 1088, 238-250 (2006).
229. Mormina, M. E., Thakur, S., Molleman, A., Whelan, C. J. & Baydoun, A. R. Cannabinoid signalling in TNF- α induced IL-8 release. *Eur J Pharmacol* (2006).
230. Raduner, S. et al. Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND - INDEPENDENT IMMUNOMODULATORY EFFECTS. *J Biol Chem* 281, 14192- 14206 (2006).
231. Alasua Del Valle, A. Implication of Cannabinoids in Neurological Diseases. *Cell Mol Neurobiol* (2006).
232. Bifulco, M., Laezza, C., Pisanti, S. & Gazerro, P. Cannabinoids and cancer: pros and cons of an antitumour strategy. *Br J Pharmacol* 148, 123-135 (2006).
233. Kogan, N. M. et al. A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells. *Mol Pharmacol* (2006).
234. Fogli, S. et al. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. *FEBS Lett* 580, 1733-1739 (2006).

235. Bari, M., Battista, N., Fezza, F., Gasperi, V. & Maccarrone, M. New insights into endocannabinoid degradation and its therapeutic potential. *Mini Rev Med Chem* 6, 257-268 (2006).
236. Fernandez-Lopez, D. et al. Characterization of the Neuroprotective Effect of the Cannabinoid Agonist WIN-55212 in an In Vitro Model of Hypoxic-Ischemic Brain Damage in Newborn Rats. *Pediatr Res* (2006).
237. Guzman, M. et al. A pilot clinical study of Delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. *Br J Cancer* (2006).
238. Sarnataro, D. et al. The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation Through A Lipid Rafts Mediated Mechanism. *Mol Pharmacol* (2006).
239. Strasser, F. et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. *J Clin Oncol* 24, 3394- 3400 (2006).
240. Carracedo, A. et al. Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress-Related Genes. *Cancer Res* 66, 6748-6755 (2006).
241. Caffarel, M. M., Sarrio, D., Palacios, J., Guzman, M. & Sanchez, C. Delta}9-Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation. *Cancer Res* 66, 6615-6621 (2006).
242. Guagnini, F. et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. *Gut* 55, 946-953 (2006).
243. Roberts, J. D., Gennings, C. & Shih, M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. *Eur J Pharmacol* 530, 54-58 (2006).
244. Eichele, K., Weinzierl, U., Ramer, R., Brune, K. & Hinz, B. R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells. *Pharm Res* 23, 90-94 (2006).
245. Rao, G. K. & Kaminski, N. E. Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels. *J Leukoc Biol* 79, 202-213 (2006).
246. Ben-Shabat, S., Hanus, L. O., Katzavian, G. & Gallily, R. New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. *J Med Chem* 49, 1113-1117 (2006).

247. Grimaldi, C. et al. Anandamide inhibits adhesion and migration of breast cancer cells. *Exp Cell Res* 312, 363-373 (2006).
248. Vignot, S. et al. [Cannabis and cancer]. *Bull Cancer* 93, 163-170 (2006).
249. Shmist, Y. A. et al. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. *Mol Cell Biochem* 283, 75-83 (2006).
250. Hamamoto, D. T., Giridharagopalan, S. & Simone, D. A. Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor- evoked hyperalgesia. *Eur J Pharmacol S* (2006).
251. Pisanti, S. et al. Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy. *J Cell Physiol S* (2006).
252. Ellert-Miklaszewska, A., Grajkowska, W., Gabrusiewicz, K., Kaminska, B. & Konarska, L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. *Brain Res S* (2006).
253. Huang, H., Nishi, K., Tsai, H. J. & Hammock, B. D. Development of highly sensitive fluorescent assays for fatty acid amide hydrolase. *Anal Biochem SO - Anal Biochem*. 2006 Dec 20;d (2006).
254. Davis, M., Maida, V., Daeninck, P. & Pergolizzi, J. The emerging role of cannabinoid neuromodulators in symptom management. *Support Care Cancer* (2006).
255. Wang, H. et al. Fatty acid amide hydrolase deficiency limits early pregnancy events. *J Clin Invest* 116, 2122-2131 (2006).
256. Jia, W. et al. Delta}9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria. *Mol Cancer Res* 4, 549-562 (2006).
257. Held-Feindt, J., Dorner, L., Sahan, G., Mehdorn, H. M. & Mentlein, R. Cannabinoid receptors in human astroglial tumors. *J Neurochem* 98, 886-893 (2006).
258. Perez, J. Combined cannabinoid therapy via an oromucosal spray. *Drugs Today (Barc)* 42, 495-503 (2006).
259. Matias, I. et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. *J Clin Endocrinol Metab* 91, 3171-3180 (2006).
260. Ben Amar, M. Cannabinoids in medicine: A review of their therapeutic potential. *J Ethnopharmacol* 105, 1-25 (2006).

261. Herrera, B. et al. The CB(2) cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. *Exp Cell Res* (2006).
262. Holland, M. L. et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. *Biochem Pharmacol* 71, 1146-1154 (2006).
263. Carracedo, A. et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. *Cancer Cell* 9, 301-312 (2006).
264. Verhoeckx, K. C. et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. *Int Immunopharmacol* 6, 656-665 (2006).
265. Singh, J. & Budhiraja, S. Therapeutic potential of cannabinoid receptor ligands: current status. *Methods Find Exp Clin Pharmacol* 28, 177-183 (2006).
266. Russo, E. & Guy, G. W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. *Med Hypotheses* 66, 234-246 (2006).
267. Vidinsky, B., Gal, P. & Mojzis, J. [Different views on the association between cannabinoids and cancer]. *Cas Lek Cesk* 145, 453-7; discussion 458-9 (2006).
268. Massi, P., Vaccani, A. & Parolaro, D. Cannabinoids, immune system and cytokine network. *Curr Pharm Des* 12, 3135-3146 (2006).
269. Huskey, A. Cannabinoids in cancer pain management. *J Pain Palliat Care Pharmacother* 20, 43-46 (2006).
270. Melamede, R. J. Endocannabinoids: Multi-scaled, Global Homeostatic Regulators of Cells and Society. *Interjournal Complex Systems* 1669 (2006).
271. Sancho, R. et al. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. *J Immunol* 175, 3990-3999 (2005).
272. Melamede, R. Cannabis and tobacco smoke are not equally carcinogenic. *Harm Reduct J* 2, 21 (2005).
273. Sun, Y. X. et al. Involvement of N-acyl ethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acyl ethanolamines in macrophages. *Biochim Biophys Acta* 1736, 211-220 (2005).
274. Kogan, N. M. Cannabinoids and cancer. *Mini Rev Med Chem* 5, 941-952 (2005).
275. Sarnataro, D. et al. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. *FEBS Lett* 579, 6343-6349 (2005).
276. Klein, T. W. Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat Rev Immunol* 5, 400-411 (2005).

277. McKallip, R. J., Nagarkatti, M. & Nagarkatti, P. S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. *J Immunol* 174, 3281-3289 (2005).
278. Tashkin, D. P. Smoked marijuana as a cause of lung injury. *Monaldi Arch Chest Dis* 63, 93-100 (2005).
279. Bari, M., Paradisi, A., Pasquariello, N. & Maccarrone, M. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. *J Neurosci Res* 81, 275- 283 (2005).
280. Nithipatikom, K. et al. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. *Biochem Biophys Res Commun* 332, 1028-1033 (2005).
281. Watanabe, K. et al. Marijuana extracts possess the effects like the endocrine disrupting chemicals. *Toxicology* 206, 471-478 (2005).
282. Sheng, W. S. et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. *Glia* 49, 211-219 (2005).
283. Ellert-Miklaszewska, A., Kaminska, B. & Konarska, L. Cannabinoids down- regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. *Cell Signal* 17, 25-37 (2005).
284. Chung, K. F. Drugs to suppress cough. *Expert Opin Investig Drugs* 14, 19-27 (2005).
285. Hall, W., Christie, M. & Currow, D. Cannabinoids and cancer: causation, remediation, and palliation. *Lancet Oncol* 6, 35-42 (2005).
286. Ramirez, B. G., Blazquez, C., Gomez del Pulgar, T., Guzman, M. & de Ceballos, M. L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. *J Neurosci* 25, 1904-1913 (2005).
287. Powles, T. et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. *Blood* 105, 1214-1221 (2005).
288. Radbruch, L. & Elsner, F. Emerging analgesics in cancer pain management. *Expert Opin Emerg Drugs* 10, 151-171 (2005).
289. Sharma, R., Tobin, P. & Clarke, S. J. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. *Lancet Oncol* 6, 93-102 (2005).
290. Roila, F. et al. Antiemetics in children receiving chemotherapy. *Support Care Cancer* 13, 129-131 (2005).
291. Kishimoto, S. et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. *J Biochem (Tokyo)* 137, 217-223 (2005).

292. Flygare, J., Gustafsson, K., Kimby, E., Christensson, B. & Sander, B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. *FEBS Lett* 579, 6885-6889 (2005).
293. Lee, S. Y., Oh, S. M., Lee, S. K. & Chung, K. H. Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. *Arch Pharm Res* 28, 1365-1375 (2005).
294. Patsos, H. A., Hicks, D. J., Greenhough, A., Williams, A. C. & Paraskeva, C. Cannabinoids and cancer: potential for colorectal cancer therapy. *Biochem Soc Trans* 33, 712-714 (2005).
295. Ortega-Gutierrez, S. et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. *FASEB J* 19, 1338-1340 (2005).
296. Lombard, C., Nagarkatti, M. & Nagarkatti, P. S. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. *Leuk Res* 29, 915-922 (2005).
297. McAllister, S. D. et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. *J Neurooncol* 74, 31-40 (2005).
298. Myrianthefs, P. M. & Batistaki, C. Cancer cachexia and immunomodulation. *J BUON* 10, 181-188 (2005).
299. Bari, M., Battista, N., Fezza, F., Finazzi-Agro, A. & Maccarrone, M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. *J Biol Chem* 280, 12212-12220 (2005).
300. Fride, E., Bregman, T. & Kirkham, T. C. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. *Exp Biol Med (Maywood)* 230, 225-234 (2005).
301. Vaccani, A., Massi, P., Colombo, A., Rubino, T. & Parolaro, D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. *Br J Pharmacol* 144, 1032-1036 (2005).
302. Guzman, M. Effects on cell viability. *Handb Exp Pharmacol* 627-642 (2005).
303. Izzo, A. A. & Coutts, A. A. Cannabinoids and the digestive tract. *Handb Exp Pharmacol* 573-598 (2005).
304. Pharmacol 573-598 (2005).
305. Burstein, S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies,
306. and clinical trials. *AAPS J* 7, E143-8 (2005).
307. Carlini, E. A. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol
308. (Delta 9-THC) on humans. *Toxicol* 44, 461-467 (2004).

309. Medveczky, M. M., Sherwood, T. A., Klein, T. W., Friedman, H. & Medveczky, P. G. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. *BMC Med* 2, 34 (2004).
310. Contassot, E. et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. *J Neuropathol Exp Neurol* 63, 956-963 (2004).
311. Juttler, E. et al. The cannabinoid dexamabinol is an inhibitor of the nuclear factor- kappa B (NF-kappa B). *Neuropharmacology* 47, 580-592 (2004).
312. Velasco, G., Galve-Roperh, I., Sanchez, C., Blazquez, C. & Guzman, M. Hypothesis: cannabinoid therapy for the treatment of gliomas? *Neuropharmacology* 47, 315-323 (2004).
313. Inui, A. [Pathogenesis and treatment of cancer anorexia-cachexia, with special emphasis on aged patients]. *Nippon Ronen Igakkai Zasshi* 41, 460-467 (2004).
314. Bifulco, M. et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. *FASEB J* 18, 1606-1608 (2004).
315. Hinz, B., Ramer, R., Eichele, K., Weinzierl, U. & Brune, K. R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. *Biochem Biophys Res Commun* 324, 621-626 (2004).
316. Rukwied, R., Gauter, B., Schley, M. & Konrad, C. [Cannabinoids-signal transduction and mode of action.]. *Schmerz* (2004).
317. Carter, G. T. & Ugalde, V. Medical marijuana: emerging applications for the management of neurologic disorders. *Phys Med Rehabil Clin N Am* 15, 943-54, ix (2004).
318. Fowler, C. J., Tiger, G., Ligresti, A., Lopez-Rodriguez, M. L. & Di Marzo, V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. *Eur J Pharmacol* 492, 1-11 (2004).
319. Carter, G. T., Weydt, P., Kyashna-Tocha, M. & Abrams, D. I. Medicinal cannabis: rational guidelines for dosing. *IDrugs* 7, 464-470 (2004).
320. Matias, I. et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. *J Pharmacol Exp Ther* 309, 745-757 (2004).
321. Duran, M., Laporte, J. R. & Capella, D. [News about therapeutic use of Cannabis and endocannabinoid system]. *Med Clin (Barc)* 122, 390-398 (2004).
322. Hart, S., Fischer, O. M. & Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated

transactivation of the epidermal growth factor receptor. *Cancer Res* 64, 1943-1950 (2004).

323. Massi, P. et al. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. *J Pharmacol Exp Ther* 308, 838-845 (2004).
324. Carracedo, A. et al. Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. *Biochem J* 380, 435-440 (2004).
325. Kraft, B. & Kress, H. G. [Cannabinoids and the immune system. Of men, mice and cells]. *Schmerz* 18, 203-210 (2004).
326. Nauck, F. & Klaschik, E. Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients. *Schmerz* 18, 197-202 (2004).
327. Martin, B. R. & Wiley, J. L. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. *J Support Oncol* 2, 305-14; discussion 314-6 (2004).
328. Kogan, N. M. et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. *J Med Chem* 47, 3800-3806 (2004).
329. Derkinderen, P., Valjent, E., Darcel, F., Damier, P. & Girault, J. A. [Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. *Rev Neurol (Paris)* 160, 639-649 (2004).
330. Rubovitch, V., Gafni, M. & Sarne, Y. The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca²⁺ flux into N18TG2 neuroblastoma cells. *Brain Res Mol Brain Res* 120, 138-144 (2004).
331. Desreumaux, P., Thuru, X. & Philippe, D. [Control of secretory diarrhea and colorectal cancer growth by cannabinoids in the gut]. *Gastroenterol Clin Biol* 28, 97 (2004).
332. Leggett, J. D. et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. *Br J Pharmacol* 141, 253-262 (2004).
333. Sancho, R. et al. Immunosuppressive activity of endovanilloids: N-arachidonoyl-dopamine inhibits activation of the NF-kappa B, NFAT, and activator protein 1 signaling pathways. *J Immunol* 172, 2341-2351 (2004).
334. Cabral, G. A. & Marciano-Cabral, F. Cannabinoid-mediated exacerbation of brain infection by opportunistic amoebae. *J Neuroimmunol* 147, 127-130 (2004).
335. Fowler, C. J. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. *Trends Pharmacol Sci* 25, 59-61 (2004).
336. Liang, Y. C., Huang, C. C. & Hsu, K. S. Therapeutic potential of cannabinoids in trigeminal neuralgia. *Curr Drug Targets CNS Neurol Disord* 3, 507-514 (2004).

337. Coutts, A. A. & Izzo, A. A. The gastrointestinal pharmacology of cannabinoids: an update. *Curr Opin Pharmacol* 4, 572-579 (2004).
338. Blazquez, C. et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. *Cancer Res* 64, 5617-5623 (2004).
339. Joseph, J., Niggemann, B., Zaenker, K. S. & Entschladen, F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. *Cancer Immunol Immunother* 53, 723-728 (2004).
340. Kalant, H. Adverse effects of cannabis on health: an update of the literature since 1996. *Prog Neuropsychopharmacol Biol Psychiatry* 28, 849-863 (2004).
341. Contassot, E., Tenan, M., Schnuriger, V., Pelte, M. F. & Dietrich, P. Y. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. *Gynecol Oncol* 93, 182-188 (2004).
342. Maccarrone, M. et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor- dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. *J Biol Chem* 278, 33896-33903 (2003).
343. Vannacci, A., Giannini, L., Masini, E. & Mannaioni, P. F. Cannabinoid-induced activation of ERK and AKT in mast cells may be mediated by intracellular NO production. *J Immunol* 171, 2767 (2003).
344. Fowler, C. J. et al. Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. *Biochem Pharmacol* 66, 757-767 (2003).
345. Sanchez, M. G., Ruiz-Llorente, L., Sanchez, A. M. & Diaz-Laviada, I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. *Cell Signal* 15, 851-859 (2003).
346. Portella, G. et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. *FASEB J* 17, 1771-1773 (2003).
347. Ligresti, A. et al. Possible endocannabinoid control of colorectal cancer growth. *Gastroenterology* 125, 677-687 (2003).

348. Croci, T., Landi, M., Galzin, A. M. & Marini, P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. *Br J Pharmacol* 140, 115-122 (2003).
349. Klein, T. W. et al. The cannabinoid system and immune modulation. *J Leukoc Biol* 74, 486-496 (2003).
350. Guzman, M. Cannabinoids: potential anticancer agents. *Nat Rev Cancer* 3, 745-755 (2003).
351. Gardner, B., Zhu, L. X., Sharma, S., Tashkin, D. P. & Dubinett, S. M. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. *FASEB J* 17, 2157-2159 (2003).
352. Ramer, R., Weinzierl, U., Schwind, B., Brune, K. & Hinz, B. Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. *Mol Pharmacol* 64, 1189-1198 (2003).
353. Wroblewski, S. T. et al. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. *J Med Chem* 46, 2110-2116 (2003).
354. Samson, M. T. et al. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. *J Immunol* 170, 4953-4962 (2003).
355. Kehl, L. J. et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. *Pain* 103, 175-186 (2003).
356. Bifulco, M. & Di Marzo, V. [The endocannabinoid system as a target for the development of new drugs for cancer therapy]. *Recenti Prog Med* 94, 194-198 (2003).
357. Vandevoorde, S., Lambert, D. M., Smart, D., Jonsson, K. O. & Fowler, C. J. N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. *Bioorg Med Chem* 11, 817-825 (2003).
358. Upham, B. L. et al. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. *Int J Cancer* 104, 12-18 (2003).
359. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids by Ag⁺ coordination tandem mass spectrometry. *Anal Biochem* 314, 8-15 (2003).
360. Blazquez, C. et al. Inhibition of tumor angiogenesis by cannabinoids. *FASEB J* 17, 529-531 (2003).
361. New toke on treating skin cancer. *Lab Anim (NY)* 32, 12 (2003).

362. Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E. & Clark, A. J. Cannabis use for chronic non-cancer pain: results of a prospective survey. *Pain* 102, 211-216 (2003).
363. Parker, L. A. et al. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. *Psychopharmacology (Berl)* 166, 156-162 (2003).
364. Walsh, D., Nelson, K. A. & Mahmoud, F. A. Established and potential therapeutic applications of cannabinoids in oncology. *Support Care Cancer* 11, 137-143 (2003).
365. Bruera, E. & Castro, M. Cannabinoids in supportive care: are they necessary? *Support Care Cancer* 11, 133-134 (2003).
366. Tarzia, G. et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. *J Med Chem* 46, 2352-2360 (2003).
367. Klegeris, A., Bissonnette, C. J. & McGeer, P. L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. *Br J Pharmacol* 139, 775-786 (2003).
368. Bash, R., Rubovitch, V., Gafni, M. & Sarne, Y. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. *Neurosignals* 12, 39-44 (2003).
369. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M. & Leon, A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lipopolysaccharide. *Glia* 41, 161-168 (2003).
370. Ihenetu, K., Molleman, A., Parsons, M. E. & Whelan, C. J. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. *Eur J Pharmacol* 458, 207-215 (2003).
371. Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. *J Clin Invest* 111, 43-50 (2003).
372. Zurier, R. B., Rossetti, R. G., Burstein, S. H. & Bidinger, B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. *Biochem Pharmacol* 65, 649-655 (2003).
373. Sarafian, T. et al. Clarifying Cb2 Receptor-dependent and Independent Effects of Thec on Human Lung Epithelial Cells. *Toxicol Appl Pharmacol* (2008).
374. Davis, M. I., Ronesi, J. & Lovinger, D. M. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. *J Biol Chem* 278, 48973-48980 (2003).

375. Sanchez, M. G., Sanchez, A. M., Ruiz-Llorente, L. & Diaz-Laviada, I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. *FEBS Lett* 555, 561-566 (2003).
376. Lavon, I. et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. *Mol Pharmacol* 64, 1334-1341 (2003).
377. Grotenhermen, F. & Muller-Vahl, K. IACM 2nd Conference on Cannabinoids in Medicine. *Expert Opin Pharmacother* 4, 2367-2371 (2003).
378. Keren, O. & Sarne, Y. Multiple mechanisms of CB1 cannabinoid receptors regulation. *Brain Res* 980, 197-205 (2003).
379. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Prudhomme, D. R. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. *Biochemistry* 42, 9041-9049 (2003).
380. Gilgun-Sherki, Y., Melamed, E., Mechoulam, R. & Offen, D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. *Pharmacol Toxicol* 93, 66-70 (2003).
381. Radbruch, L. & Nauck, F. [A review of side effects and complications with cannabinoid treatment]. *Schmerz* 17, 274-279 (2003).
382. Glaser, S. T. et al. Evidence against the presence of an anandamide transporter. *Proc Natl Acad Sci U S A* 100, 4269-4274 (2003).
383. Jonsson, K. O. et al. AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. *Arch Toxicol* 77, 201-207 (2003).
384. Hinz, B., Ramer, R. & Brune, K. Induction of COX-2 expression by the endocannabinoid derivative R(+)-methanandamide. *Adv Exp Med Biol* 525, 145-152 (2003).
385. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet* 42, 327-360 (2003).
386. Croxford, J. L. Therapeutic potential of cannabinoids in CNS disease. *CNS Drugs* 17, 179-202 (2003).
387. Reggio, P. H. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. *Curr Pharm Des* 9, 1607-1633 (2003).
388. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. *Drugs R D* 4, 306-309 (2003).

389. Gallily, R. et al. gamma-Irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured HL-60 Myeloblastic Leukemia Cells. *Leuk Lymphoma* 44, 1767-1773 (2003).
390. Gomez Del Pulgar, T., De Ceballos, M. L., Guzman, M. & Velasco, G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. *J Biol Chem* 277, 36527- 36533 (2002).
391. Kozak, K. R. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. *J Biol Chem* 277, 44877-44885 (2002).
392. Hashibe, M., Ford, D. E. & Zhang, Z. F. Marijuana smoking and head and neck cancer. *J Clin Pharmacol* 42, 103S-107S (2002).
393. Rubovitch, V., Gafni, M. & Sarne, Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. *Brain Res Mol Brain Res* 101, 93-102 (2002).
394. Hinnebusch, B. F., Meng, S., Wu, J. T., Archer, S. Y. & Hodin, R. A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. *J Nutr* 132, 1012-1017 (2002).
395. Inui, A. Cancer anorexia-cachexia syndrome: current issues in research and management. *CA Cancer J Clin* 52, 72-91 (2002).
396. Carter, G. T. & Weydt, P. Cannabis: old medicine with new promise for neurological disorders. *Curr Opin Investig Drugs* 3, 437-440 (2002).
397. Germain, N., Boichot, E., Advenier, C., Berdyshev, E. V. & Lagente, V. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF- alpha production by human mononuclear cells. *Int Immunopharmacol* 2, 537-543 (2002).
398. Smith, P. F. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. *Curr Opin Investig Drugs* 3, 859-864 (2002).
399. Bifulco, M. & Di Marzo, V. Targeting the endocannabinoid system in cancer therapy: a call for further research. *Nat Med* 8, 547-550 (2002).
400. Sarafian, T. A., Kouyoumjian, S., Tashkin, D. & Roth, M. D. Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole. *Toxicol Lett* 133, 171-179 (2002).
401. McKallip, R. J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. *Blood* 100, 627-634 (2002).

402. Parolaro, D., Massi, P., Rubino, T. & Monti, E. Endocannabinoids in the immune system and cancer. *Prostaglandins Leukot Essent Fatty Acids* 66, 319-332 (2002).
403. Fernandez-Ruiz, J., Lastres-Becker, I., Cabranes, A., Gonzalez, S. & Ramos, J. A. Endocannabinoids and basal ganglia functionality. *Prostaglandins Leukot Essent Fatty Acids* 66, 257-267 (2002).
404. Kozak, K. R. & Marnett, L. J. Oxidative metabolism of endocannabinoids. *Prostaglandins Leukot Essent Fatty Acids* 66, 211-220 (2002).
405. Pertwee, R. G. & Ross, R. A. Cannabinoid receptors and their ligands. *Prostaglandins Leukot Essent Fatty Acids* 66, 101-121 (2002).
406. Esposito, G. et al. The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. *J Biol Chem* 277, 50348-50354 (2002).
407. Galve-Roperh, I., Rueda, D., Gomez del Pulgar, T., Velasco, G. & Guzman, M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. *Mol Pharmacol* 62, 1385-1392 (2002).
408. Maccarrone, M., Pauselli, R., Di Rienzo, M. & Finazzi-Agro, A. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. *Biochem J* 366, 137-144 (2002).
409. van der Stelt, M. et al. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. *J Med Chem* 45, 3709-3720 (2002).
410. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated tyrosine phosphorylation of focal adhesion kinase-related non-kinase. *FEBS Lett* 525, 164- 168 (2002).
411. Ek, S., Hogerkorp, C. M., Dictor, M., Ehinger, M. & Borrebaeck, C. A. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. *Cancer Res* 62, 4398-4405 (2002).
412. De Petrocellis, L. et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. *Fundam Clin Pharmacol* 16, 297-302 (2002).
413. Ishii, I. & Chun, J. Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors. *Neuroreport* 13, 593-596 (2002).

414. Jorda, M. A. et al. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. *Blood* 99, 2786-2793 (2002).
415. Gomez del Pulgar, T., Velasco, G., Sanchez, C., Haro, A. & Guzman, M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. *Biochem J* 363, 183-188 (2002).
416. Zurcher, G. [Anorectic syndrome]. *Z Gastroenterol* 40 Suppl 1, S71-S5 (2002).
417. Melck, D. et al. Cannabimimetic eicosanoids in cancer and inflammation: an
418. update. *Adv Exp Med Biol* 507, 381-386 (2002).
419. Kalant, H. Medicinal use of cannabis: history and current status. *Pain Res Manag* 6,
420. 80-91 (2001).
421. Walker, J. M., Strangman, N. M. & Huang, S. M. Cannabinoids and pain. *Pain Res*
422. *Manag* 6, 74-79 (2001).
423. Mechoulam, R. & Hanu, L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. *Pain Res Manag* 6, 67-73 (2001).
424. Ramer, R., Brune, K., Pahl, A. & Hinz, B. R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. *Biochem Biophys Res Commun* 286, 1144-1152 (2001).
425. Recht, L. D. et al. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. *Biochem Pharmacol* 62, 755-763 (2001).
426. ElSohly, M. A., deWit, H., Wachtel, S. R., Feng, S. & Murphy, T. P. Delta9-tetrahydrocannabinol as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. *J Anal Toxicol* 25, 565-571 (2001).
427. Jamshidi, N. & Taylor, D. A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. *Br J Pharmacol* 134, 1151-1154 (2001).
428. Roth, M. D. et al. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. *Am J Respir Cell Mol Biol* 24, 339-344 (2001).
429. Tashkin, D. P. Airway effects of marijuana, cocaine, and other inhaled illicit agents. *Curr Opin Pulm Med* 7, 43-61 (2001).
430. Pagotto, U. et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a

- direct role of cannabinoids on hormone modulation at the human pituitary level. *J Clin Endocrinol Metab* 86, 2687-2696 (2001).
431. Day, T. A., Rakhshan, F., Deutsch, D. G. & Barker, E. L. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. *Mol Pharmacol* 59, 1369-1375 (2001).
432. Campbell, F. A. et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. *BMJ* 323, 13-16 (2001).
433. Moody, J. S., Kozak, K. R., Ji, C. & Marnett, L. J. Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. *Biochemistry* 40, 861-866 (2001). Maccarrone, M., Attina, M., Cartoni, A., Bari, M. & Finazzi-Agro, A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. *J Neurochem* 76, 594-601 (2001).
434. Velasco, L., Ruiz, L., Sanchez, M. G. & Diaz-Laviada, I. delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. *Eur J Biochem* 268, 531-535 (2001).
435. Darmani, N. A. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. *Neuropsychopharmacology* 24, 198-203 (2001).
436. Bifulco, M. et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. *FASEB J* 15, 2745-2747 (2001).
437. Jacobsson, S. O., Wallin, T. & Fowler, C. J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. *J Pharmacol Exp Ther* 299, 951-959 (2001).
438. Smith, S. R., Terminelli, C. & Denhardt, G. Modulation of cytokine responses in *Corynebacterium parvum*-primed endotoxemic mice by centrally administered cannabinoid ligands. *Eur J Pharmacol* 425, 73-83 (2001).
439. Di Marzo, V. et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. *Biochem J* 358, 249-255 (2001).
440. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. *J Neurosci Res* 65, 346-353 (2001).

441. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Schneider, C. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. *J Biol Chem* 276, 30072-30077 (2001).
442. Sanchez, C. et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. *Cancer Res* 61, 5784-5789 (2001).
443. Sarafian, T. A., Tashkin, D. P. & Roth, M. D. Marijuana smoke and Delta(9)-tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. *Toxicol Appl Pharmacol* 174, 264-272 (2001).
444. Esposito, G., Izzo, A. A., Di Rosa, M. & Iuvone, T. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. *J Neurochem* 78, 835-841 (2001).
445. Jonsson, K. O., Vandevoorde, S., Lambert, D. M., Tiger, G. & Fowler, C. J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. *Br J Pharmacol* 133, 1263-1275 (2001).
446. Jacobsson, S. O. & Fowler, C. J. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. *Br J Pharmacol* 132, 1743-1754 (2001).
447. Bisogno, T. et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. *Eur J Biochem* 268, 1982-1989 (2001).
448. Ripamonti, C. & Dickerson, E. D. Strategies for the treatment of cancer pain in the new millennium. *Drugs* 61, 955-977 (2001).
449. Guzman, M., Sanchez, C. & Galve-Roperh, I. Control of the cell survival/death decision by cannabinoids. *J Mol Med* 78, 613-625 (2001).
450. Kaferstein, H. & Sticht, G. Comparison of nonradioactive microtiter plate enzyme immunoassays for the sensitive detection of fentanyl. *Forensic Sci Int* 113, 353-357 (2000).
451. Di, M., Bisogno, T. & De Petrocellis, L. Endocannabinoids: new targets for drug development. *Curr Pharm Des* 6, 1361-1380 (2000).
452. Gallily, R., Breuer, A. & Mechoulam, R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. *Eur J Pharmacol* 406, R5-7 (2000).
453. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G. & Finazzi-Agro, A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. *J Biol Chem* 275, 31938-31945 (2000).

454. Klein, T. W., Lane, B., Newton, C. A. & Friedman, H. The cannabinoid system and cytokine network. *Proc Soc Exp Biol Med* 225, 1-8 (2000).
455. Carriot, F. & Sasco, A. J. [Cannabis and cancer]. *Rev Epidemiol Sante Publique* 48, 473-483 (2000).
456. Maccarrone, M., Salvati, S., Bari, M. & Finazzi-Agro. Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxigenase pathway of the arachidonate cascade. *Biochem Biophys Res Commun* 278, 576-583 (2000).
457. De Petrocellis, L., Melck, D., Bisogno, T. & Di Marzo, V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. *Chem Phys Lipids* 108, 191-209 (2000).
458. Ho, B. Y. et al. Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. *Endocrinology* 141, 1675-1685 (2000).
459. MacCarrone, M. et al. Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. *Eur J Biochem* 267, 2991-2997 (2000).
460. Molnar, J. et al. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivatives. *Anticancer Res* 20, 861-867 (2000).
461. Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. *Nat Med* 6, 313-319 (2000).
462. Zhu, L. X. et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. *J Immunol* 165, 373-380 (2000).
463. Puffenbarger, R. A., Boothe, A. C. & Cabral, G. A. Cannabinoids inhibit LPS- inducible cytokine mRNA expression in rat microglial cells. *Glia* 29, 58-69 (2000).
464. Melck, D. et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. *Endocrinology* 141, 118-126 (2000).
465. Yea, S. S., Yang, K. H. & Kaminski, N. E. Role of nuclear factor of activated T- cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. *J Pharmacol Exp Ther* 292, 597-605 (2000).
466. Jacobsson, S. O., Rongard, E., Stridh, M., Tiger, G. & Fowler, C. J. Serum- dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. *Biochem Pharmacol* 60, 1807-1813 (2000).

467. Rubino, T. et al. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. *Neuropharmacology* 39, 1331-1336 (2000).
468. Gomez del Pulgar, T., Velasco, G. & Guzman, M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. *Biochem J* 347, 369-373 (2000).
469. Han, D. S. et al. Synthesis and cytotoxic effects of deoxy-tomentellin. *Arch Pharm Res* 23, 121-127 (2000).
470. Benard, J. [Cannabinoids, among others, send malignant glial tumors to nirvana.]. *Bull Cancer* 87, 299-300 (2000).
471. Muthian, S., Nithipatikom, K., Campbell, W. B. & Hillard, C. J. Synthesis and characterization of a fluorescent substrate for the N-arachidonylethanolamine (anandamide) transmembrane carrier. *J Pharmacol Exp Ther* 293, 289-295 (2000).
472. Smith, S. R., Terminelli, C. & Denhardt, G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. *J Pharmacol Exp Ther* 293, 136-150 (2000).
473. Di Marzo, V., Melck, D., De Petrocellis, L. & Bisogno, T. Cannabimimetic fatty acid derivatives in cancer and inflammation. *Prostaglandins Other Lipid Mediat* 61, 43-61 (2000).
474. Lorenzo Fernandez, P. [Potential therapeutic usefulness of cannabis and cannabinoids]. *An R Acad Nac Med (Madr)* 117, 595-605; discussion 616-24 (2000).
475. Ruiz, L., Miguel, A. & Diaz-Laviada, I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. *FEBS Lett* 458, 400-404 (1999).
476. Lambert, D. M. et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. *Biochim Biophys Acta* 1440, 266-274 (1999).
477. Gorter, R. W. Cancer cachexia and cannabinoids. *Forsch Komplementarmed* 6 Suppl 3, 21-22 (1999).
478. Mechoulam, R. Recent advantages in cannabinoid research. *Forsch Komplementarmed* 6 Suppl 3, 16-20 (1999).
479. Studies of high-dose chemotherapy with stem cell support for breast cancer. *Am J Health Syst Pharm* 56, 940 (1999).

480. Valk, P. J. et al. Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. *J Virol* 73, 3595-3602 (1999).
481. Mukhopadhyay, S., Cowsik, S. M., Lynn, A. M., Welsh, W. J. & Howlett, A. C. Regulation of Gi by the CB1 cannabinoid receptor C-terminal juxtamembrane region: structural requirements determined by peptide analysis. *Biochemistry* 38, 3447-3455 (1999).
482. Sarafian, T. A., Magallanes, J. A., Shau, H., Tashkin, D. & Roth, M. D. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. *Am J Respir Cell Mol Biol* 20, 1286-1293 (1999).
483. Basavarajappa, B. S. & Hungund, B. L. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N- arachidonoylphosphatidylethanolamine in SK-N-SH cells. *J Neurochem* 72, 522- 528 (1999).
484. Melck, D. et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. *Biochem Biophys Res Commun* 262, 275-284 (1999).
485. Kenney, S. P. et al. Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. *Am J Obstet Gynecol* 181, 491-497 (1999).
486. Masset, D., Bourdon, J. H., Arditti-Djiane, J. & Jouglard, J. [Impact of delta-9-tetrahydrocannabinol and its metabolites on the immune system]. *Acta Clin Belg Suppl* 1, 39-43 (1999).
487. Berglund, B. A., Boring, D. L. & Howlett, A. C. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. *Adv Exp Med Biol* 469, 527-533 (1999).
488. Sanchez, C., Galve-Roperh, I., Canova, C., Brachet, P. & Guzman, M. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. *FEBS Lett* 436, 6-10 (1998).
489. Di Marzo, V. et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. *FEBS Lett* 436, 449-454 (1998).
490. Maccarrone, M. et al. Anandamide hydrolysis by human cells in culture and brain. *J Biol Chem* 273, 32332-32339 (1998).
491. Srivastava, M. D., Srivastava, B. I. & Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. *Immunopharmacology* 40, 179-185 (1998).

492. Herrstedt, J., Aapro, M. S., Smyth, J. F. & Del Favero, A. Corticosteroids, dopamine antagonists and other drugs. *Support Care Cancer* 6, 204-214 (1998).
493. Bisogno, T. et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. *Eur J Biochem* 254, 634-642 (1998).
494. Baek, S. H. et al. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. *Arch Pharm Res* 21, 353-356 (1998).
495. Bruera, E. & Neumann, C. M. The uses of psychotropics in symptom management in advanced cancer. *Psychooncology* 7, 346-358 (1998).
496. De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. *Proc Natl Acad Sci U S A* 95, 8375-8380 (1998).
497. Bisogno, T. et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. *Biochem Biophys Res Commun* 248, 515-522 (1998).
498. Zurier, R. B. et al. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. *Arthritis Rheum* 41, 163-170 (1998).
499. Derocq, J. M. et al. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. *FEBS Lett* 425, 419-425 (1998).
500. Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D. & De Petrocellis, L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. *Biochem J* 331, 15-19 (1998).
501. Di Toro, R., Campana, G., Sciarretta, V., Murari, G. & Spampinato, S. Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells. *Life Sci* 63, PL197-204 (1998).
502. Ongradi, J., Specter, S., Horvath, A. & Friedman, H. Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells. *Pathol Oncol Res* 4, 191-199 (1998).
503. Bisogno, T., Sepe, N., De Petrocellis, L., Mechoulam, R. & Di Marzo, V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. *Biochem Biophys Res Commun* 239, 473-479 (1997).
504. Molina-Holgado, F., Lledo, A. & Guaza, C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. *Neuroreport* 8, 1929-1933 (1997).

505. Voth, E. A. & Schwartz, R. H. Medicinal applications of delta-9- tetrahydrocannabinol and marijuana. *Ann Intern Med* 126, 791-798 (1997).
506. McPartland, J. M. & Pruitt, P. L. Medical marijuana and its use by the immunocompromised. *Altern Ther Health Med* 3, 39-45 (1997).
507. Bisogno, T. et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. *Biochem J* 322, 671-677 (1997).
508. Abood, M. E., Ditto, K. E., Noel, M. A., Showalter, V. M. & Tao, Q. Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. *Biochem Pharmacol* 53, 207-214 (1997).
509. Ruh, M. F., Taylor, J. A., Howlett, A. C. & Welshons, W. V. Failure of cannabinoid compounds to stimulate estrogen receptors. *Biochem Pharmacol* 53, 35-41 (1997).
510. Deutsch, D. G. et al. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. *Biochem Biophys Res Commun* 231, 217-221 (1997).
511. Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T. & Kaminski, N. E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. *Toxicol Appl Pharmacol* 142, 278-287 (1997).
512. Sanchez, C., Velasco, G. & Guzman, M. Delta9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. *Brain Res* 767, 64-71 (1997).
513. Axelrod, R. S. Antiemetic therapy. *Compr Ther* 23, 539-545 (1997).
514. Goodman, M. Risk factors and antiemetic management of chemotherapy-induced
515. nausea and vomiting. *Oncol Nurs Forum* 24, 20-32 (1997).
516. Hunter, S. A. & Burstein, S. H. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. *Life Sci* 60, 1563-1573 (1997).
517. Di Marzo, V., De Petrocellis, L., Sugiura, T. & Waku, K. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-
518. arachidonoyl-glycerol, in mouse neuroblastoma cells. *Biochem Biophys Res Commun* 227, 281-288 (1996). Lew, G. M. Tau protein after delta-9-tetrahydrocannabinol in a human neuroblastoma cell line. *Gen Pharmacol* 27, 1141-1143 (1996).
519. NIH. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). *Natl Toxicol Program Tech Rep Ser S 446*, 1-317 (1996).

520. Bhargava, H. N., House, R. V., Thorat, S. N. & Thomas, P. T. Cellular immune function in mice tolerant to or abstinent from l-trans-delta 9-tetrahydrocannabinol. *Pharmacology* 52, 271-282 (1996).
521. Chan, P. C., Sills, R. C., Braun, A. G., Haseman, J. K. & Bucher, J. R. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. *Fundam Appl Toxicol* 30, 109-117 (1996).
522. Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. *Biochem J* 316, 977-984 (1996).
523. Ho, B. Y. & Zhao, J. Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells. *Neurosci Lett* 212, 123-126 (1996).
524. Zheng, Z. M. & Specter, S. C. Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages. *Int J Immunopharmacol* 18, 53-68 (1996).
525. Abood, M. E. & Martin, B. R. Molecular neurobiology of the cannabinoid receptor. *Int Rev Neurobiol* 39, 197-221 (1996).
526. Mackie, K., Lai, Y., Westenbroek, R. & Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci* 15, 6552- 6561 (1995).
527. Burnette-Curley, D. & Cabral, G. A. Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta 9tetrahydrocannabinol. *Proc Soc Exp Biol Med* 210, 64-76 (1995).
528. Burstein, S. H. & Hunter, S. A. Stimulation of anandamide biosynthesis in N- 18TG2 neuroblastoma cells by delta 9-tetrahydrocannabinol (THC). *Biochem Pharmacol* 49, 855-858 (1995).
529. Klein, T. W., Newton, C., Zhu, W., Daaka, Y. & Friedman, H. delta 9-Tetrahydrocannabinol, cytokines, and immunity to *Legionella pneumophila*. *Proc Soc Exp Biol Med* 209, 205-212 (1995).
530. Frider, E. et al. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. *J Pharmacol Exp Ther* 272, 699-707 (1995).
531. Gibertini, M., Newton, C., Friedman, H. & Klein, T. W. IL-1 beta and TNF alpha modulate delta 9-tetrahydrocannabinol-induced catalepsy in mice. *Pharmacol Biochem Behav* 50, 141-146 (1995).

532. Hirst, R. A. & Lambert, D. G. Do SH-SY5Y human neuroblastoma cells express cannabinoid receptors? *Biochem Soc Trans* 23, 418S (1995).
533. Cabral, G. A., Toney, D. M., Fischer-Stenger, K., Harrison, M. P. & Marciano- Cabral, F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. *Life Sci* 56, 2065-2072 (1995).
534. Nelson, K., Walsh, D., Deeter, P. & Sheehan, F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. *J Palliat Care* 10, 14-18 (1994).
535. Koutek, B. et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. *J Biol Chem* 269, 22937-22940 (1994).
536. Kusher, D. I., Dawson, L. O., Taylor, A. C. & Djeu, J. Y. Effect of the psychoactive metabolite of marijuana, delta 9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes. *Cell Immunol* 154, 99- 108 (1994).
537. Zheng, Z. M. & Specter, S. Suppression by delta-9-tetrahydrocannabinol of lipopolysaccharide-induced and intrinsic tyrosine phosphorylation and protein expression in mouse peritoneal macrophages. *Biochem Pharmacol* 47, 2243-2252 (1994).
538. Trisler, K. & Specter, S. Delta-9-tetrahydrocannabinol treatment results in a suppression of interleukin-2-induced cellular activities in human and murine lymphocytes. *Int J Immunopharmacol* 16, 593-603 (1994).
539. Vigano, A., Watanabe, S. & Bruera, E. Anorexia and cachexia in advanced cancer patients. *Cancer Surv* 21, 99-115 (1994).
540. Cabral, G. A. & Fischer-Stenger, K. Inhibition of macrophage inducible protein expression by delta-9-tetrahydrocannabinol. *Life Sci* 54, 1831-1844 (1994).
541. Shivers, S. C., Newton, C., Friedman, H. & Klein, T. W. delta 9- Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. *Life Sci* 54, 1281-1289 (1994).
542. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. *Nature* 365, 61-65 (1993).
543. Mackie, K., Devane, W. A. & Hille, B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. *Mol Pharmacol* 44, 498-503 (1993).
544. Klein, T. W., Newton, C., Widen, R. & Friedman, H. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with *Legionella pneumophila*. *J Pharmacol Exp Ther* 267, 635-640 (1993).

545. Melvin, L. S. et al. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. *Mol Pharmacol* 44, 1008-1015 (1993).
546. Bruera, E. Is the pharmacological treatment of cancer cachexia possible? *Support Care Cancer* 1, 298-304 (1993).
547. Bouaboula, M. et al. Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem* 214, 173-180 (1993).
548. Fischer-Stenger, K., Dove Pettit, D. A. & Cabral, G. A. Delta 9- tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post- translational events. *J Pharmacol Exp Ther* 267, 1558-1565 (1993).
549. Burnette-Curley, D., Marciano-Cabral, F., Fischer-Stenger, K. & Cabral, G. A. delta-9- Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette-Guerin-activated macrophages. *Int J Immunopharmacol* 15, 371- 382 (1993).
550. Tchekmedyan, N. S., Halpert, C., Ashley, J. & Heber, D. Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy. *JPEN J Parenter Enteral Nutr* 16, 88S-92S (1992).
551. Zheng, Z. M., Specter, S. & Friedman, H. Inhibition by delta-9- tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. *Int J Immunopharmacol* 14, 1445-1452 (1992).
552. Mackie, K. & Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. *Proc Natl Acad Sci U S A* 89, 3825-3829 (1992).
553. Mitchelson, F. Pharmacological agents affecting emesis. A review (Part I). *Drugs* 43, 295-315 (1992).
554. Caulfield, M. P. & Brown, D. A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. *Br J Pharmacol* 106, 231-232 (1992).
555. Bruera, E. Current pharmacological management of anorexia in cancer patients. *Oncology (Huntingt)* 6, 125-30; discussion 132, 137 (1992).
556. Campbell, M. & Bateman, D. N. Pharmacokinetic optimisation of antiemetic therapy. *Clin Pharmacokinet* 23, 147-160 (1992).
557. Nahas, G. & Latour, C. The human toxicity of marijuana. *Med J Aust* 156, 495-497 (1992).
558. Bruera, E. Clinical management of anorexia and cachexia in patients with advanced cancer. *Oncology* 49 Suppl 2, 35-42 (1992).

559. Turkanis, S. A., Karler, R. & Partlow, L. M. Differential effects of delta-9-tetrahydrocannabinol and its 11-hydroxy metabolite on sodium current in neuroblastoma cells. *Brain Res* 560, 245-250 (1991).
560. Wang, M., Richards, A. L., Friedman, H. & Djeu, J. Y. Selective inhibition of natural killer but not natural cytotoxic activity in a cloned cell line by delta-9-tetrahydrocannabinol. *J Leukoc Biol* 50, 192-197 (1991).
561. Watzl, B., Scuderi, P. & Watson, R. R. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. *Adv Exp Med Biol* 288, 63-70 (1991).
562. Watzl, B., Scuderi, P. & Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. *Int J Immunopharmacol* 13, 1091-1097 (1991).
563. Tashkin, D. P. Pulmonary complications of smoked substance abuse. *West J Med* 152, 525-530 (1990).
564. Johnson, B. A. Psychopharmacological effects of cannabis. *Br J Hosp Med* 43, 114- 6, 118-20, 122 (1990).
565. Stewart, D. J. Cancer therapy, vomiting, and antiemetics. *Can J Physiol Pharmacol* 68, 304-313 (1990).
566. Tortorice, P. V. & O'Connell, M. B. Management of chemotherapy-induced nausea and vomiting. *Pharmacotherapy* 10, 129-145 (1990).
567. Howlett, A. C., Scott, D. K. & Wilken, G. H. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. *Biochem Pharmacol* 38, 3297-3304 (1989).
568. Shook, J. E. & Burks, T. F. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. *J Pharmacol Exp Ther* 249, 444-449 (1989).
569. Grunberg, S. M. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. *Blood Rev* 3, 216-221 (1989).
570. McCabe, M. et al. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. *Invest New Drugs* 6, 243-246 (1988).
571. Dill, J. A. & Howlett, A. C. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. *J Pharmacol Exp Ther* 244, 1157-1163 (1988).
572. Kawakami, Y. et al. Suppression by delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity. *Int J Immunopharmacol* 10, 485-488 (1988).

573. Triozzi, P. L. & Laszlo, J. Optimum management of nausea and vomiting in cancer chemotherapy. *Drugs* 34, 136-149 (1987).
574. Little, P. J., Kaplan, N. C. & Martin, B. R. Pharmacological profile of delta 9-THC carbamate. *Alcohol Drug Res* 7, 517-523 (1987).
575. Howlett, A. C. Regulation of adenylate cyclase in a cultured neuronal cell line by marijuana constituents, metabolites of delta-9-tetrahydrocannabinol, and synthetic analogs having psychoactivity. *NIDA Res Monogr* 79, 148-157 (1987).
576. Roffman, R. A. Stress inoculation training in the control of THC toxicities. *Int J Addict* 21, 883-896 (1986).
577. Specter, S. C. et al. Marijuana effects on immunity: suppression of human natural killer cell activity of delta-9-tetrahydrocannabinol. *Int J Immunopharmacol* 8, 741- 745 (1986).
578. Dodds, L. J. The control of cancer chemotherapy-induced nausea and vomiting. *J Clin Hosp Pharm* 10, 143-166 (1985).
579. Citron, M. L. et al. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. *Cancer Treat Rep* 69, 109-112 (1985).
580. Perlin, E. et al. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. *J Pharm Sci* 74, 171-174 (1985).
581. Ungerleider, J. T. et al. THC or Compazine for the cancer chemotherapy patient-- the UCLA study. Part II: Patient drug preference. *Am J Clin Oncol* 8, 142-147 (1985).
582. Bakowski, M. T. Advances in anti-emetic therapy. *Cancer Treat Rev* 11, 237-256 (1984).
583. Kaplan, N. C. Dichloroethyl carbamoyl ester of delta-9-tetrahydrocannabinol. Chemical synthesis and biological testing and evaluation as a potentially site- specific anti-tumor agent. *Sci Sin [B]* 27, 1048-1058 (1984).
584. Hiller, E. & Gerhartz, H. [New aspects in the antiemetic therapy of cytostatic drug-induced vomiting]. *Klin Wochenschr* 62, 441-445 (1984).
585. Stoudemire, A., Cotanch, P. & Laszlo, J. Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis. *Arch Intern Med* 144, 1029-1033 (1984)Eyre, H. J. & Ward, J. H. Control of cancer chemotherapy-induced nausea and vomiting. *Cancer* 54, 2642-2648 (1984).
586. Frytak, S., Moertel, C. G. & Rubin, J. Metabolic studies of delta-9- tetrahydrocannabinol in cancer patients. *Cancer Treat Rep* 68, 1427-1431 (1984).
587. Hogan, P., Sharpe, M., Smedley, H. & Sikora, K. Cannabinoids and hCG levels in patients with testicular cancer. *Lancet* 2(8359), 1144 (1983).

588. Treffert, D. A. & Joranson, D. E. delta 9-Tetrahydrocannabinol and therapeutic research legislation for cancer patients. *JAMA* 249, 1469-1472 (1983).
589. Carey, M. P., Burish, T. G. & Brenner, D. E. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. *Ann Intern Med* 99, 106-114 (1983).
590. Laszlo, J. Nausea and vomiting as major complications of cancer chemotherapy. *Drugs* 25 Suppl 1, 1-7 (1983).
591. Heim, M. E. [Cannabis and cannabinoids. Possibilities of their therapeutic use]. *Fortschr Med* 100, 343-346 (1982).
592. Tetrahydrocannabinol (THC) for cancer patients. A review of the National Cancer Institute program in Wisconsin. *Wis Med J* 81, 24 (1982).
593. Laszlo, J. Treatment of nausea and vomiting caused by cancer chemotherapy. *Cancer Treat Rev* 9 Suppl B, 3-9 (1982).
594. Ungerleider, J. T. et al. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. *Cancer* 50, 636-645 (1982).
595. Joss, R. A. et al. Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. *Cancer Chemother Pharmacol* 9, 61-64 (1982).
596. Goldstein, M. S. & Williams, F. F. How we comply with federal guidelines on THC dispensing. *Pharm Times* 47, 32-36 (1981).
597. Poster, D. S., Penta, J. S., Bruno, S. & Macdonald, J. S. delta 9- tetrahydrocannabinol in clinical oncology. *JAMA* 245, 2047-2051 (1981).
598. Anderson, P. O. & McGuire, G. G. Delta-9-tetrahydrocannabinol as an antiemetic. *Am J Hosp Pharm* 38, 639-646 (1981).
599. Procedure for obtaining THC for cancer patients. *JAMA* 246, 15-19 (1981).
600. Sweet, D. L., Miller, N. J., Weddington, W., Senay, E. & Sushelsky, L. delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. *J Clin Pharmacol* 21, 70S-75S (1981). Garb, S. Cannabinoids in the management of severe nausea and vomiting from cancer chemotherapy. Some additional considerations. *J Clin Pharmacol* 21, 57S- 59S (1981).
601. Benowitz, N. L. & Jones, R. T. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. *J Clin Pharmacol* 21, 214S-223S (1981).
602. Dow, G. J. & Meyers, F. H. The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy. *J Clin Pharmacol* 21, 128S-132S (1981).

603. Abraham, D., Pina, K. R. & Davignon, J. P. Mechanism for national distribution of delta 9-tetrahydrocannabinol (NSC-134454). *J Clin Pharmacol* 21, 122S-127S (1981).
604. Scigliano, J. A. THC therapeutic research by independent and state-sponsored investigators: a historical review. *J Clin Pharmacol* 21, 113S-121S (1981).
605. Penta, J. S., Poster, D. S., Bruno, S. & Macdonald, J. S. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. *J Clin Pharmacol* 21, 11S-22S (1981).
606. Levitt, M. et al. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. *J Clin Pharmacol* 21, 103S- 109S (1981).
607. Gunby, P. Many cancer patients receiving THC as antiemetic. *JAMA* 245, 1515, 1518 (1981).
608. Chang, A. E. et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. *Cancer* 47, 1746-1751 (1981).
609. Sallan, S. E. & Cronin, C. M. Is THC an effective antiemetic for cancer patients? Opinion 2. *CA Cancer J Clin* 30, 283-285 (1980).
610. Frytak, S. Is THC an effective antiemetic for cancer patients? Opinion 1. *CA Cancer J Clin* 30, 278-282 (1980).
611. Winokur, S. H., Baker, J. J., Lokey, J. L. & Price, N. A. Marijuana for nausea and vomiting in cancer patients. *J Med Assoc Ga* 69, 919-920 (1980).
612. Lucas, V. S. J. & Laszlo, J. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. *JAMA* 243, 1241-1243 (1980).
613. Sallan, S. E., Cronin, C., Zelen, M. & Zinberg, N. E. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9- tetrahydrocannabinol and prochlorperazine. *N Engl J Med* 302, 135-138 (1980).
614. Levy, J. A. & Heppner, G. H. Immunosuppression by marijuana and its cannabinoid constituents. *J Immunopharmacol* 2, 159-177 (1980).
615. Ekert, H., Waters, K. D., Jurk, I. H., Mabilia, J. & Loughnan, P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9- tetrahydrocannabinol. *Med J Aust* 2, 657-659 (1979).
616. Frytak, S. et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. *Ann Intern Med* 91, 825-830 (1979).

617. Chang, A. E. et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. *Ann Intern Med* 91, 819-824 (1979).
618. Mechoulam, R. & Carlini, E. A. Toward drugs derived from cannabis. *Naturwissenschaften* 65, 174-179 (1978).
619. Warner, W., Harris, L. S. & Carchman, R. A. Inhibition of corticosteroidogenesis by delta-9-tetrahydrocannabinol. *Endocrinology* 101, 1815-1820 (1977).
620. Friedman, M. A. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas. *Cancer Biochem Biophys* 2, 51-54 (1977).
621. White, A. C., Munson, J. A., Munson, A. E. & Carchman, R. A. Effects of delta-9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. *J Natl Cancer Inst* 56, 655-658 (1976).
622. Carchman, R. A., Harris, L. S. & Munson, A. E. The inhibition of DNA synthesis by cannabinoids. *Cancer Res* 36, 95-100 (1976).
623. Munson, A. E., Harris, L. S., Friedman, M. A., Dewey, W. L. & Carchman, R. A. Antineoplastic activity of cannabinoids. *J Natl Cancer Inst* 55, 597-602 (1975).
624. Noyes, R. J., Brunk, S. F., Avery, D. A. & Canter, A. C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. *Clin Pharmacol Ther* 18, 84-89 (1975).
625. Noyes, R. J., Brunk, S. F., Baram, D. A. & Canter, A. Analgesic effect of delta-9-tetrahydrocannabinol. *J Clin Pharmacol* 15, 139-143 (1975).